argenex SE $ARGX Shares Sold by Ethic Inc.

Ethic Inc. trimmed its holdings in argenex SE (NASDAQ:ARGX) by 14.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 1,003 shares of the company’s stock after selling 175 shares during the period. Ethic Inc.’s holdings in argenex were worth $562,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. grew its stake in shares of argenex by 14.8% in the first quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock valued at $99,886,000 after buying an additional 21,805 shares in the last quarter. Amundi lifted its holdings in argenex by 8.1% during the 1st quarter. Amundi now owns 6,351 shares of the company’s stock worth $3,747,000 after buying an additional 478 shares during the last quarter. Voya Investment Management LLC lifted its holdings in argenex by 5.2% during the 1st quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock worth $8,822,000 after buying an additional 735 shares during the last quarter. Wealth Management Associates Inc. purchased a new stake in argenex during the 1st quarter worth about $268,000. Finally, Royal Bank of Canada lifted its holdings in argenex by 0.9% during the 1st quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock worth $22,673,000 after buying an additional 353 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Trading Up 0.8%

Shares of NASDAQ ARGX opened at $836.39 on Wednesday. The stock has a fifty day moving average price of $759.62 and a 200 day moving average price of $649.70. The company has a market cap of $51.50 billion, a P/E ratio of 42.89, a P/E/G ratio of 0.90 and a beta of 0.46. argenex SE has a 12-month low of $510.05 and a 12-month high of $855.46.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.90. The company had revenue of $866.79 million during the quarter, compared to analysts’ expectations of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. On average, sell-side analysts forecast that argenex SE will post 3.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ARGX. JPMorgan Chase & Co. lifted their target price on argenex from $775.00 to $830.00 and gave the stock an “overweight” rating in a research report on Monday, August 4th. Truist Financial boosted their target price on argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Bank of America boosted their price target on argenex from $880.00 to $887.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Wells Fargo & Company upped their target price on argenex from $741.00 to $756.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Finally, Wedbush boosted their price target on argenex from $800.00 to $880.00 and gave the company an “outperform” rating in a report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $817.53.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.